Breast Cancer

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.

Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Reva K. Basho, MD, discusses the evolution of therapeutic sequencing in HER2-positive breast cancer.

Leslie L. Montgomery, MD, and Tara M. Balija, MD, discuss the benefits of a novel reflector device in patients with breast cancer, its efficacy in identifying clipped axillary lymph nodes, and the potential future use of this device in other cancer types.

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.